

Raffaella Sordella

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2272275/publications.pdf>

Version: 2024-02-01

10
papers

11,774
citations

1039406

9
h-index

1372195

10
g-index

15
all docs

15
docs citations

15
times ranked

12534
citing authors

#	ARTICLE	IF	CITATIONS
1	Patient-derived xenografts and in vitro model show rationale for imatinib mesylate repurposing in HEY1-NCoA2-driven mesenchymal chondrosarcoma. <i>Laboratory Investigation</i> , 2022, 102, 1038-1049.	1.7	1
2	An epigenetic switch regulates the ontogeny of AXL-positive/EGFR-TKI-resistant cells by modulating miR-335 expression. <i>ELife</i> , 2021, 10, .	2.8	7
3	Rapid and tunable method to temporally control gene editing based on conditional Cas9 stabilization. <i>Nature Communications</i> , 2017, 8, 14370.	5.8	128
4	TGF- β 2 reduces DNA ds-break repair mechanisms to heighten genetic diversity and adaptability of CD44+/CD24 ^{low} cancer cells. <i>ELife</i> , 2017, 6, .	2.8	37
5	TP53 exon-6 truncating mutations produce separation of function isoforms with pro-tumorigenic functions. <i>ELife</i> , 2016, 5, .	2.8	47
6	The Evolution of Mutations: From Loss-of-Function to Separation-of-Function Mutants. <i>Journal of Cancer Biology & Research</i> , 2016, 4, .	0.5	15
7	p53 β is a transcriptionally inactive p53 isoform able to reprogram cells toward a metastatic-like state. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, E3287-96.	3.3	73
8	TGF- β 2 IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 15535-15540.	3.3	356
9	Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. <i>Nature Genetics</i> , 2005, 37, 1315-1316.	9.4	468
10	Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non-Small-Cell Lung Cancer to Gefitinib. <i>New England Journal of Medicine</i> , 2004, 350, 2129-2139.	13.9	10,632